Business description: Alexion Pharmaceuticals, Inc.

Number of employees: 3,837
Sales by Activity: Alexion Pharmaceuticals, Inc.
| Fiscal Period: December | 2019 (USD) | 2020 (USD) |
|---|---|---|
Biotechnology | 4.99B | 6.07B |
Geographical breakdown of sales: Alexion Pharmaceuticals, Inc.
| Fiscal Period: December | 2019 (USD) | 2020 (USD) |
|---|---|---|
United States | 2.76B | 3.6B |
Europe | 1.21B | 1.33B |
Asia Pacific | 528M | 664M |
Rest of World | 493M | 475M |
Executive Committee: Alexion Pharmaceuticals, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Dunoyer
CEO | Chief Executive Officer | 73 | - |
Sean Christie
DFI | Director of Finance/CFO | 53 | 2021-07-31 |
Doyle Shane
COO | Chief Operating Officer | - | - |
| Chief Tech/Sci/R&D Officer | - | 2021-06-30 | |
Ruth Diazaraque
CTO | Chief Tech/Sci/R&D Officer | - | 2023-05-31 |
Company details: Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc.
121 Seaport Boulevard
02210, Boston
+(475) 230-2596
http://www.alexion.com
Group companies: Alexion Pharmaceuticals, Inc.
| Name | Category and Sector |
|---|---|
Alexion Business Services Pvt Ltd.
Alexion Business Services Pvt Ltd. Data Processing ServicesTechnology Services Provides data processing and preparation services |
Data Processing Services
|
Alexion Pharma International Operations Ltd.
Alexion Pharma International Operations Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products |
Pharmaceuticals: Major
|
Alexion Pharma Holding Unlimited Co.
Alexion Pharma Holding Unlimited Co. Pharmaceuticals: MajorHealth Technology Develops biologic therapeutic products |
Pharmaceuticals: Major
|
Alexion Pharma GmbH
Alexion Pharma GmbH BiotechnologyHealth Technology Operates as a biopharmaceutical company focused on developing life-changing therapies for people living with rare disorders |
Biotechnology
|
Other Pharmaceuticals
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -2.39% | -6.36% | +47.10% | +149.66% | 1,024B | ||
| -0.76% | -4.34% | +52.04% | +49.09% | 618B | ||
| -2.33% | -4.60% | +25.55% | +64.44% | 443B | ||
| +0.68% | -1.14% | +38.47% | +33.36% | 349B | ||
| -1.66% | -3.13% | +32.18% | +39.79% | 297B | ||
| -8.96% | -9.23% | +3.57% | +3.64% | 264B | ||
| -1.37% | -5.71% | -2.10% | -44.43% | 209B | ||
| -1.63% | +0.69% | +27.62% | +64.23% | 208B | ||
| +0.72% | +0.48% | +15.88% | +73.64% | 162B | ||
| Average | -1.54% | -1.76% | +26.70% | +48.16% | 397.08B | |
| Weighted average by Cap. | -0.98% | -3.02% | +34.56% | +70.69% |

















